Brief: Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million
13/03/2025 21:37
March 13 (Reuters) - Regulus Therapeutics Inc RGLS.O: REGULUS THERAPEUTICS Q4 OPERATING EXPENSES USD 13.746 MILLION REGULUS THERAPEUTICS Q4 INCOME FROM OPERATIONS USD -13.746 MILLION REGULUS THERAPEUTICS Q4 BASIC EPS USD -0.2 REGULUS THERAPEUTICS Q4 PRETAX PROFIT USD -12.791 MILLION REGULUS THERAPEUTICS Q4 NET INCOME USD -12.791 MILLION REGULUS THERAPEUTICS: CO EXPECTS ITS CASH RUNWAY TO EXTEND INTO EARLY 2026 Source text: ID:nPn6r2WCPa Further company coverage: RGLS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview